<DOC>
	<DOC>NCT01278342</DOC>
	<brief_summary>This study will assess the efficacy of 8 months treatment of Sandostatin® LAR® High Dose monotherapy or Sandostatin® LAR® High Dose in combination either with growth hormone antagonist or dopamine agonist to control biochemical parameters (GH and insulin-like growth factor I [IGF I]) of acromegalic patients not achieving biochemical normalization at conventional regimen.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<criteria>• Patient with a biochemically documented active acromegaly, not adequately controlled by somatostatinanalogues at conventional regimen as follow : mean 1hour GH &gt; 2.5 ng/mL and elevated IGF1 (adjusted for age and gender) Patient with reduction of either mean fasting GH at least 50% or IGF1 at least 25% from any medical pretreatment level Patient currently receiving somatostatinanalogues at conventional regimen (maximum registered dose) for at least 6 months before inclusion Newly diagnosed or previously medically untreated acromegalic patient Concomitant treatment with GHreceptor antagonist Concomitant treatment with dopamineagonist Symptomatic cholelithiasis or choledocolithiasis Liver transaminases (ALT, AST) elevated, but &gt; 3 times upper normal limit (according to local laboratory) Previous gammaknife radiotherapy for treatment of acromegaly Compression of the optic chiasm causing visual field defect Any medical conditions contraindicated in the Summary of Product Characteristic (SPC) of all drugs Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sandostatin LAR</keyword>
	<keyword>High Dose</keyword>
	<keyword>GH-receptor antagonist</keyword>
	<keyword>combination with dopamine-agonist</keyword>
	<keyword>acromegalic patients</keyword>
	<keyword>octreotide acetate</keyword>
	<keyword>Somavert</keyword>
	<keyword>Dostinex</keyword>
	<keyword>pegvisomant</keyword>
	<keyword>cabergoline</keyword>
	<keyword>not adequately controlled</keyword>
	<keyword>active acromegaly</keyword>
</DOC>